Wake Forest Institute for Regenerative Medicine creates a STEM-focused master’s program

The RegenMed Hub in downtown Winston-Salem now features a new master’s degree program Focuses on educating future generations of STEM professionals and business leaders in the field of regenerative medicine.

The program represents a collaboration between Wake Forest University School of Medicine and the university’s Institute of Regenerative Medicine within the Innovation Quarter.

STEM stands for Science, Technology, Engineering, and Mathematics.

The Translational Biotechnology program features two tracks – Research and Business – with the goal of preparing graduates to lead the movement of new treatments from the laboratory to the clinic.

Coursework will be taught by the Institute’s regenerative medicine experts.

People also read…

“After graduation, you will be ready to pursue a variety of STEM careers that are relevant to current and changing times based on the knowledge, skills, and abilities you have acquired,” according to the program’s website.

“The broader workforce will be eager to access critical new skills in market assessment, project management, product development, and finance, that were previously underrepresented or non-existent in STEM graduate education that you cultivated as a student.

“You’ll take with you the expertise required for entrepreneurship, scaling up biotherapeutics, or biomanufacturing (regulatory affairs, process development, quality control), many of which are simultaneously required to work in biotechnology or the academic sectors with which the industry collaborates.”

Tracey Cresswell, director of the new program and associate professor at the Institute, said:

Criswell said the certification program is designed for anyone planning to work in environments such as:

  • Institutions of academic research and education, including undergraduate and professional schools;
  • Pharmaceutical industry;
  • Biotech or pharmaceutical start-ups; And the
  • Government agencies, such as the Department of Defense, the National Institutes of Health, or the Food and Drug Administration.

“The demand for talent with different qualifications and degrees in the life sciences continues to grow across North Carolina,” said Nancy Johnston, executive director of the Piedmont Triad at the NC Biotechnology Center.

“Specifically, this new transitional biotechnology degree program is: important to the growing pool of regenerative medicine; a critical component to advancing localized research and development; and relevant to addressing the required skill sets across the marketing chain.”

RegenMed اتصال Connection

Dr. Anthony Atala, director of the institute, said the degree program is “an integral part of the RegenMed Hub.” The centre, branded ReMDO, debuted locally in June.

Atala describes RegenMed Hub as “a thriving regenerative medicine ecosystem in North Carolina that provides access to unparalleled resources for education, product and manufacturing development, with the ultimate goal of improving patient care.”

The Science/Research Focused Track is intended for students with a four-year undergraduate degree in biomedical sciences who are primarily interested in research in academia or industry.

Students will pursue a research project culminating in a written thesis and defense.

The business-focused track is aimed at students who are already professionals in their field (scientists or non-scientists), but would like to gain knowledge about starting or leading companies operating in the biotechnology field.

The asynchronous online coursework will allow these students to earn a Master of Science degree while still working.

Students will complete a capstone project geared towards their area of ​​interest.

Both tracks require external training – local or virtual – with a partner biotechnology organization.

A Certificate in Translational Biotechnology is also offered, consisting of 15 credits of course work tailored to the student’s needs.

The research track requires full-time study and on-campus participation is expected. Research Track students conduct research at WFIRM in support of a thesis.

The Business Track is a part-time program, designed for working professionals, that does not require participation in Winston-Salem.

Students enrolled in both tracks are required to commit to a minimum of five semesters (20 months). A slowed-down study plan may be an option for business students, allowing students to move at a slower pace with fewer courses per semester.

The deadline for applications is March 1. Complete information about the program and admission can be found at https://school.wakehealth.edu/education-and-training/graduate-programs/translational-biotechnology-ms.

“Establishing this program will enable companies that develop RegenMed products to succeed without leaving North Carolina,” Johnston said. “It’s a distinction for state, region, and Winston-Salem.”

Other RegenMed Items

In September, the institute said that MIMEDX, based in Marietta, Ga. , takes up space in the RegeneratOR Innovation Accelerator.

The accelerator helps emerging regenerative medicine companies and growth companies with new or emerging technologies move from research to commercialization.

MIMEDX is a placenta biological company A pioneer in placental tissue engineering.

In August, RTT Medical announced its rental plans at the accelerator.

MIMEDX said it has distributed more than two million tissue grafts to date, primarily to meet the needs of patients with acute and chronic non-healing wounds.

Part of his clinical research targets a late-stage biological pipeline aimed at reducing pain and improving function for patients with degenerative musculoskeletal diseases.

Space opened up in the accelerator and the RegenMed Hub was designed “to further advance the sciences relating to the application of placenta technologies in the multiple areas of wound care and regenerative medicine.”

MIMEDX aims to develop new products and improve manufacturing processes “in a way that advances the delivery of safe, innovative and evidence-based technologies to patients in a cost-effective manner.”

RTT Medical, founded in 2021, produces regenerative tissue technologies for wound management including partial and complete wounds; pressure ulcers; Diabetic ulcers Venous ulcers Chronic vascular ulcers. pitted / scaly wounds; Surgical Wounds Trauma Wounds and Draining Wounds.

All of these wounds are referred to as soft tissue repair. The company’s products have a 510(k) permit from the Food and Drug Administration.

The company’s number one market product is XCelliStem Wound Powder, a customized blend of substances that facilitate the healing and repair of wounds and burns.

The main attraction of the accelerator is the ReMDO test bed, which provides biomanufacturing equipment, industry expertise and talent to support new prototypes and commercial product development.

The RegeneratOR Test Bed laboratory space, which debuted in June 2021, is designed to pool resources to advance the field of regenerative medicine nationally and create a driver for economic development for the region and North Carolina.

Eleven collaborating companies, including Oracle, BioSpherix, and PHC, formerly known as Panasonic Healthcare Corp. , RegeneratOR test bed launch feasible.

Atala said about $50 million has been invested in the RegeneratOR Test Bed, primarily from industry and government.

Another speaker, Chris Chung, CEO of the North Carolina Economic Development Partnership, said in June 2021 that the initiative offers tremendous economic potential for Winston Salem, Trinity and the entire state of North Carolina.

“All of you at Winston-Salem have a front seat to what is going on, thanks to the work of Dr. Atala and colleagues,” Chung said.

“You are all in the driving seat on how this industry continues to evolve and meet the needs of human health medicine.”

Axiom Space

In April, the institute and RegenMed announced a partnership with Axiom Space, which is developing the first commercial space station.

Institute officials described the partnership as the “next frontier” in research and manufacturing.

“We can literally take the field of regenerative medicine to a whole new level,” Atala said.

The biggest expected benefit is the research, which was initially conducted on the International Space Station, “will be free from the constraints of gravity, and will offer significant potential and benefits,” according to the entities.

“This will enable our scientific research teams to develop biofabrication to deliver new treatments that cannot be developed on Earth, and treatments for conditions that affect the human body when exposed to the harsh environment of space travel,” Atala said.

The primary goal of the partnership is to further accelerate the translation of regenerative medicine technologies into products and services for patients.

Axiom is chartered by ReMDO’s Innovation Accelerator to access its test bed.

“This partnership paves the way for a full-fledged commercial industry aboard the Axiom space station,” Atala said.

Leave a Comment